胰岛素治疗是否会影响动脉多普勒指数在妊娠期间因妊娠期糖尿病而复杂的怀孕中?
Libera Troìa1,2, Stefania Ferrari1, Anna Dotta1
1Department of Gynaecology and Obstetrics, University Hospital Maggiore della Carità, 28100 Novara, Italy.
Healthcare (Basel, Switzerland)
|October 16, 2024
概括
孕妇妊娠期糖尿病 (GDM) 的胰岛素治疗与动脉脉动指数 (UA-PI) 的降低有关,这表明血液流动阻抗较低. 这种效应在妊娠第三季度更为明显.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 心血管生理学心血管生理学
背景情况:
- 孕期糖尿病 (GDM) 是一种常见的妊娠并发症.
- 提高母体葡萄糖对胎儿胎盘循环的影响,特别是在胰岛素治疗中,需要进一步阐明.
研究的目的:
- 评价胰岛素治疗对动脉多普勒指数对患有GDM的母亲胎儿的影响.
- 为了比较不同GDM治疗组和健康对照组之间的多普勒指数.
主要方法:
- 对447个GDM怀孕和100个健康对照的回顾性观察研究.
- 动脉脉动指数 (UA-PI) 测量在妊娠28周,32周和36周.
- 将GDM患者分为营养治疗,长效胰岛素和组合胰岛素组.
主要成果:
- 在所有组中,UA-PI在妊娠期间下降.
- 结合胰岛素治疗显示出较低的UA-PI趋势,比单独使用长效胰岛素更低.
- 在联合胰岛素组与32周和36周的单独营养治疗相比,观察到UA-PI显著降低.
结论:
- 对GDM的胰岛素治疗与动脉血流阻抗降低有关.
- 这种血液动力学变化在怀孕的第三个三个月更为明显.
- 需要进行进一步的研究,以将UA-PI变化与怀孕结果以及葡萄糖管理的确切影响相关联.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes
881
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
881
Insulin: Dosing Regimen and Adverse Effects
152
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
152
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178


